MEDIPOST signs a joint research agreement with LG Chemical

MEDIPOST, ends phase I and II clinical trials with PNEUMOSTEM, the effective treatment of BPD for preterm infants

MEDIPOST, acquires a Japanese patent for the mesenchymal stem cell culture method

MEDIPOST Clears Product Approval Renewal of CARTISTEM by the Ministry of Food and Drug Safety(MFDS)

MEDIPOST Registers US Patent for the Treatment of Lung Diseases

Results from the US Clinical Trial of PNEUMOSTEM for Treating Lung Disease is Published in International Journal

MEDIPOST, announces a domestic and international clinical experience at the ISCT annual meeting

MEDIPOST, announces the clinical trial achievements at Bio USA

MEDIPOST’s Injectable Cell Therapeutic for Knee Osteoarthritis Receives Phase 1 Clinical Trial Approval

MEDIPOST Registers the Canadian Patent for a Mesenchymal Stem Cell Culture Method

MEDIPOST Registers European Patent for the Mesenchymal Stem Cell Culture Method

MEDIPOST’s PNEUMOSTEM Receives Fast Track Designation from the US FDA